Mobile website
Archive > Volume 24 Issue 9 > 2017,24(9):979-983. DOI:10.3872/j.issn.1007-385X.2017.09.009 Prev Next
Clinical Research
Expression of lncRNA RP11-259P1.1 in esophageal squamous cell cancer and its correlation with clinical prognosis
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To investigate lncRNA RP11-259P1.1 expression in esophageal squamous cell carcinoma (ESCC) and to explore its correlation with clinicopathological features and prognosis. Methods: 130 cases of prima-ry ESCC cancer tissues and the corresponding paracancerous tissues resected during surgery from January 1, 2012to December 31, 2016 at the Affiliated Hospital of Southwest Medical University, as well as human ESCC cell lines KYSE510, Eca109 and esophageal epithelial cell line Het-1A were collected for this study. The method of quantita-tive real-time polymerase chain reaction (qPCR) was used to measure lncRNA RP11-259P1.1 expression in speci-mens and cells, and the association between lncRNA RP11-259P1.1 expression in speciments and clinicopathologi-cal features or prognosis was analyzed. Results: The expression of lncRNA RP11-259P1.1 in esophageal cancer cells and cancer tissues was significantly higher than that in normal esophageal epithelial cells and para-cancerous tissues (all P＜0.01). High expression of lncRNA RP11-259P1.1 was significantly associated with tumor size, TNM stage, lymph node metastases and chemoradiotherapy sensitivity (CRT) (P<0.05), but not associated with ages, gen-der, tumor location, smoking (P>0.05). In 63 cases of patients receiving neoadjuvant radiochemotherapy (CRT+S),by comparing patients with high lncRNA RP11-259P1.1 expression and low expression, (1) pathological complete remission (pCR) rate in low expression patients was significantly increased (60% vs 21.21%, P<0.05); (2) the treat-ment efficacy of pre-operative CRT in patients with low expression was better (P<0.05); (3) median progress-free survival (PFS) and overall survival (OS) of patients with low expression was significantly prolonged ([28.00±2.47]months vs [17.00±1.90] months，P<0.01; [41.57±2.45] months vs [30.00±2.55] months，P<0.01). lncRNA RP11-259P1.1 can be used as a prognostic factor for patients with esophageal cancer (P<0.05). Conclusion: The expres-sion of lncRNA RP11-259P1.1 could serve as a potential molecular marker to predict the prognosis and pre-opera-tive CRT treatment efficacy of ESCC patients, and patients with low lncRNA PR11-259P1.1 expression might achieve a better treatment efficacy from pre-operative CRT.
Keywords:
Project Supported:
Clc Number:
